Sociedad Americana de Hirudoterapia

A global view of digital replantation and revascularization

Review published in Clin Plast Surg (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosTang JB et al. · Clinics in plastic surgery, 2020

Abstract

Survival rates of digital replantation vary in different regions and countries, and Asian surgeons see more challenging cases and have developed some unique methods. Replantation of multiple digits in one or both hands can follow a structure-by-structure method or a digit-by-digit method. For replanting all 10 digits, 3 or 4 teams should be organized. Flow-through flaps, often venous flaps, can be taken from the distal forearm or lower extremity to repair defects of soft tissues and arteries. A pedicled digital artery flap from the adjacent digit can also repair tissue defects and supply blood to the replanted digit.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAmputation, TraumaticFemaleFinger InjuriesFingersHumansMaleMicrosurgeryPlastic Surgery ProceduresReplantationSurgical FlapsTreatment Outcome

Resumen

Global review of digital replantation/revascularization survival rates across regions. Discusses multi-team protocols, flow-through and pedicled flaps for multi-digit and total-hand replantations.

Por qué esto importa para la hirudoterapia

Global digital-replantation review providing regional outcome context for adjunct leech use.

Citación

A global view of digital replantation and revascularization.

Tang JB et al. · Clinics in plastic surgery, 2020

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.